Fresenius Medical Care AG (FMS)
NYSE: FMS · Real-Time Price · USD
23.24
-0.01 (-0.04%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Fresenius Medical Care AG Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Fresenius Medical Care AG stock has a target of 26, which predicts an increase of 11.88% from the current stock price of 23.24.
Analyst Consensus: Hold
* Price targets were last updated on May 21, 2026.
Analyst Ratings
The average analyst rating for Fresenius Medical Care AG stock from 6 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 2 | 2 | 2 | 2 |
| Buy | 0 | 1 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Hold Maintains $26 | Hold | Maintains | $26 | +11.88% | May 21, 2026 |
Financial Forecast
Revenue This Year
19.46B
from 19.63B
Decreased by -0.84%
Revenue Next Year
20.17B
from 19.46B
Increased by 3.62%
EPS This Year
3.93
from 4.28
Decreased by -8.27%
EPS Next Year
4.40
from 3.93
Increased by 12.18%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 20.8B | 22.0B | |
| Avg | 19.5B | 20.2B | |
| Low | 19.0B | 19.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.9% | 13.1% | |
| Avg | -0.8% | 3.6% | |
| Low | -3.1% | 1.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.11 | 5.60 | |
| Avg | 3.93 | 4.40 | |
| Low | 3.71 | 3.71 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -4.0% | 42.6% | |
| Avg | -8.3% | 12.2% | |
| Low | -13.4% | -5.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.